Toxicology Report

Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -

Malonic Acid

What is Malonic Acid?

CAS No: 141-82-2

Malonic Acid is an acid compound whose pharmaceutical applications span formulation excipient use, synthetic reagent functions, and in some cases direct therapeutic activity. The pKₐ of Malonic Acid determines the ionisation equilibrium relevant to its GI absorption, renal clearance, and tissue distribution when present as an impurity or excipient component at trace levels. Occupational exposure to Malonic Acid in manufacturing environments is primarily assessed for irritant corrosive effects on the respiratory tract and skin, with OEL values reflecting the concentration producing no adverse local tissue effects in the most sensitive exposure studies.

Genotoxicity data for Malonic Acid are assessed under the ICH M7 framework for carcinogenic impurity qualification. A positive Ames test result without a clear non-genotoxic mechanism triggers linear extrapolation from carcinogenicity data, with the acceptable intake derived from the TD50 or the default value of 1.5 µg/day for lifetime exposure pro

To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).

Request Your Assessment

Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.

View Inquiry List →
What's included:
Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
9,000+
Toxicological & Exposure
Assessment Reports Delivered
70+
Subject Matter Experts
across global operations
12
In-House Ex-Agency
Toxicologists
3
Certification Bodies:
ERT · UKRT · DABT

Assessment Methodology

Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.

EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)

Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.

PIC/S – Shared Facilities and Contamination Control Guidance

Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.

ICH Q9 – Quality Risk Management

Provides a structured methodology for risk identification, assessment, control, communication, and review.

ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)

Applied for compounds with potential mutagenic or genotoxic concerns.

Risk-Based Toxicological Assessment

Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.

Weight-of-Evidence (WoE) Approach

Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.

Report Preparation Process

Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.

01

Comprehensive Data Review

Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.

02

Scientific Evaluation

Identification of critical endpoints and selection of appropriate exposure limits.

03

PDE / HBEL Derivation

Transparent and scientifically justified calculations aligned with global toxicological principles.

04

Ex-Agency Expert Review (Our Differentiator)

Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.

05

Final Report Delivery

Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).

Why Masuu Global?

Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.

✓

Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.

✓

Inspection-ready reports — scientifically defensible and audit-prepared from day one.

✓

Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).

✓

Practical implementation recommendations that translate science into actionable contamination control.

✓

Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.

✓

Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.

Ready to request your assessment?

Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.

Frequently Asked Questions

Malonic Acid is a simple dicarboxylic acid with three carbon atoms. It is commonly used as a building block in chemical and pharmaceutical synthesis, for example in the preparation of esters and other derivatives. Because it may be handled as a reagent or intermediate, a toxicological review helps define exposure limits and handling controls.

A PDE or ADE sets a health-based limit on daily exposure to Malonic Acid from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.

Yes, where relevant. The assessment reviews the available genotoxicity information for Malonic Acid and may use structure-based evaluation when data are limited. ICH M7 principles may apply if relevant, for example when a substance could be a potentially mutagenic impurity in a later product. The conclusions and assumptions are documented.

A PDE is a health-based limit on daily exposure from residual carryover into the next product, usually set for the oral route. An OEL is a workplace limit, normally expressed as an airborne concentration over a stated time period, that protects people handling Malonic Acid. The two serve different purposes, so one should not replace the other without justification.

Not necessarily. A PDE or ADE is derived for a defined route of exposure, often oral for carryover into the next product. Extrapolating to inhalation or dermal exposure needs scientific justification, so the report should state the route, scope, and assumptions behind the value.

An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.

An OEB places Malonic Acid in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.

Manufacturing steps such as charging, transfer, sampling, and cleaning can each create different exposure opportunities. The assessment considers how Malonic Acid is handled at each step, including its physical form and the controls in place. This links the exposure limit to realistic operations and supports practical risk management.

Limited public data can be the case for chemical intermediates. A risk-based approach can then draw on related compounds, structure-based evaluation, and the data that do exist, with each assumption documented. For potentially mutagenic compounds, ICH M7 principles may be applied where applicable.

Uncertainty factors account for differences between test species and humans, variability between individuals, study duration and quality, and gaps in the available data. Each factor must be scientifically justified and documented so reviewers can follow how the final health-based limit was reached.

Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.

Use the Request Your Assessment option on this page and add Malonic Acid to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.

Book a Demo